FierceBiotech |
Lilly pays $55M for rights to KeyBioscience's diabetes assets
FierceBiotech Eli Lilly is paying $55 million upfront for the rights to KeyBioscience's pipeline of treatments for Type 2 diabetes and other metabolic conditions. The agreement gives Lilly the global rights to phase 2 synthetic peptide dual amylin and calcitonin ... Lilly Acquires DACRA Pipeline from KeyBioScience, with Diabetes Treatments in Mind Hunting new deals, Eli Lilly buddies up on diabetes R&D with $55M ... |
Social Plugin